Chinese drug giant Shanghai Fosun Pharmaceutical Group Co. Ltd. has bought 86 per cent stake in Gland Pharma for about $1.4 billion.
This is billed as India's largest inbound acquisition in 2016.
Hong Kong-listed Fosun is controlled by billionaire Guo Guangchang while Hyderabad-based Gland Pharma is backed by global private equity firm KKR & Co.
While Fosun bought 86 per cent stake, the rest will remain with the promoter's family, sources in Gland Pharma said.
The deal is likely to be announced officially in a day or two.
Established in 1978, Gland Pharma has seven factories in Hyderabad and Visakhapatnam, manufacturing a variety of injectables and high quality APIs (active pharmaceutical ingredients).
It sells generic injectables, primarily in the US and Europe.
Gland had sales of around Rs 1,300 crore last fiscal, with 30 per cent Compound Annual Growth Rate (CAGR).
--IANS
ms/lok/vt
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
